These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25322329)

  • 21. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
    Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Third-generation antibody drug conjugates for cancer therapy--a balancing act.
    Vankemmelbeke M; Durrant L
    Ther Deliv; 2016; 7(3):141-4. PubMed ID: 26893243
    [No Abstract]   [Full Text] [Related]  

  • 23. Antibody-drug conjugates: Intellectual property considerations.
    Storz U
    MAbs; 2015; 7(6):989-1009. PubMed ID: 26292154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel data in metastatic breast cancer.
    Vahdat LT
    Clin Adv Hematol Oncol; 2013; 11(10 Suppl 16):13-5. PubMed ID: 24637556
    [No Abstract]   [Full Text] [Related]  

  • 25. NICE confirms advanced breast cancer drug is too expensive for NHS.
    White C
    BMJ; 2014 Aug; 349():g5078. PubMed ID: 25106642
    [No Abstract]   [Full Text] [Related]  

  • 26. [Perjeta: treating an aggressive breast cancer].
    Perspect Infirm; 2013; 10(5):64. PubMed ID: 24358682
    [No Abstract]   [Full Text] [Related]  

  • 27. Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review.
    Kalsi R; Feigenberg S; Kwok Y; Tkaczuk K; Mehta M; Chumsri S
    Clin Breast Cancer; 2015 Apr; 15(2):e163-6. PubMed ID: 25454740
    [No Abstract]   [Full Text] [Related]  

  • 28. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
    Krop I; Winer EP
    Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted therapies: TH3RESA trial, overcoming hurdles in breast cancer.
    Villanueva MT
    Nat Rev Clin Oncol; 2014 Jul; 11(7):379. PubMed ID: 24913372
    [No Abstract]   [Full Text] [Related]  

  • 30. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.
    Diéras V; Harbeck N; Budd GT; Greenson JK; Guardino AE; Samant M; Chernyukhin N; Smitt MC; Krop IE
    J Clin Oncol; 2014 Sep; 32(25):2750-7. PubMed ID: 25024070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA
    J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer].
    Kitagawa D; Toi M
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():396-401. PubMed ID: 17682183
    [No Abstract]   [Full Text] [Related]  

  • 33. New developments for antibody-drug conjugate-based therapeutic approaches.
    de Goeij BE; Lambert JM
    Curr Opin Immunol; 2016 Jun; 40():14-23. PubMed ID: 26963132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-DM1-related carotenoderma and hand-foot syndrome.
    Dholaria B; Srinivasan S
    Lancet; 2015 Apr; 385(9977):1509-10. PubMed ID: 25933279
    [No Abstract]   [Full Text] [Related]  

  • 35. Antibody-drug conjugates.
    Zolot RS; Basu S; Million RP
    Nat Rev Drug Discov; 2013 Apr; 12(4):259-60. PubMed ID: 23535930
    [No Abstract]   [Full Text] [Related]  

  • 36. Unsustained response to brentuximab as single agent therapy in a patient with CD30 positive angiosarcoma.
    Holm MP; Hjorthaug K; Bærentzen S; Safwat AA
    Acta Oncol; 2016; 55(2):251-3. PubMed ID: 25914931
    [No Abstract]   [Full Text] [Related]  

  • 37. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
    Yam C; Rauch GM; Rahman T; Karuturi M; Ravenberg E; White J; Clayborn A; McCarthy P; Abouharb S; Lim B; Litton JK; Ramirez DL; Saleem S; Stec J; Symmans WF; Huo L; Damodaran S; Sun R; Moulder SL
    Invest New Drugs; 2021 Apr; 39(2):509-515. PubMed ID: 32984932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy: what progress in the last 5 years?
    Hamilton A; Hortobagyi G
    J Clin Oncol; 2005 Mar; 23(8):1760-75. PubMed ID: 15755984
    [No Abstract]   [Full Text] [Related]  

  • 39. Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage.
    Kolarich AR; Reynolds BA; Heldermon CD
    Acta Oncol; 2014 Oct; 53(10):1434-6. PubMed ID: 24834794
    [No Abstract]   [Full Text] [Related]  

  • 40. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
    Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.